Cost-Effectiveness of Nivolumab-Ipilimumab Combination Therapy Compared with Monotherapy for First-Line Treatment of Metastatic Melanoma in the United States.
Oh A, Tran DM, McDowell LC, Keyvani D, Barcelon JA, Merino O, Wilson L.
Oh A, et al.
J Manag Care Spec Pharm. 2017 Jun;23(6):653-664. doi: 10.18553/jmcp.2017.23.6.653.
J Manag Care Spec Pharm. 2017.
PMID: 28530525
Free PMC article.
METHODS: A 3-state Markov model (PD-L1 positive stable disease, PD-L1 negative stable disease, and progression and/or death) was developed using a U.S. societal perspective with a lifetime time horizon of 14.5 years. ...The manuscript was written by Oh …
METHODS: A 3-state Markov model (PD-L1 positive stable disease, PD-L1 negative stable disease, and progression and/or death) was deve …